Together, this suggests that while the tethered IL-12 can help overcome immunotherapy resistance mechanisms by repolarizing suppressive tumor immune cells, in doing so, it also drives a PD-L1–based secondary resistance mechanism. This evidence concerns the gene CD274 and neoplasm.